We are proud to announce that PhenoPath is now part of AmeriPath.
The MYD88 L265P mutation is detected in ~90% of lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM) cases, ~30% of activated/non-germinal center type diffuse large B cell lymphomas, ~40% of central nervous system lymphomas, and ~50% of IgM monoclonal gammopathies of undetermined significance (IgM-MGUS). Of note, the presence of an MYD88 L265P mutation has been associated with a higher risk progression in patients with IgM-MGUS. However, the MYD88 L265P mutation is not exclusively identified in these neoplasms and has been reported in other diagnostic entitites.
CPT Code(s): 81305 (reference only; CPTs may vary)
Turnaround Time: Within 4-8 business days of receipt
Formalin-fixed, paraffin-embedded (FFPE) tissue block, 10 FFPE tissue slides, or peripheral blood or bone marrow in EDTA or heparin.